文献速递神经肌肉病

大麻素口腔喷雾剂治疗运动神经元病痉挛的2期试验

Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Neurol · 2018-12-13

这项在意大利4个中心开展的随机双盲安慰剂对照2期试验,纳入60例运动神经元病患者,评估含δ-9-四氢大麻酚和大麻二酚的口腔喷雾剂(nabiximols)对痉挛的疗效。药物耐受良好,无严重不良事件。

要点

  • nabiximols可能改善运动神经元病患者的痉挛症状。
  • 6周时改良Ashworth量表评分组间差异有统计学意义。
  • 药物耐受良好,无严重不良事件,无因不良事件退出。

核心结论

  • 在这项概念验证试验中,nabiximols对运动神经元病患者的痉挛症状有积极效果,安全性和耐受性可接受。

研究设计与样本

  • 研究者发起的随机、双盲、安慰剂对照2期临床试验,在意大利4个三级运动神经元病中心开展。
  • 纳入60例18-80岁、符合修订El Escorial标准或Pringle标准的运动神经元病患者,随机分配至nabiximols组或安慰剂组,治疗6周。
  • 最终分析59例(nabiximols组29例,安慰剂组30例),主要终点为基线至6周改良Ashworth量表评分变化。

主要发现

  • nabiximols耐受良好,双盲阶段无参与者退出,无严重不良事件发生。

关键数值与推荐

  • 治疗前14天按预定递增方案自滴定,最大24小时12次actuation,随后维持剂量4周。

临床怎么用

  • 对于运动神经元病相关痉挛患者,nabiximols可作为潜在对症治疗选择,但需在更大规模临床试验中进一步验证。

局限性

  • 本研究为2期概念验证试验,样本量较小(最终分析59例),结果需在更大规模临床试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spasticity is a major determinant of disability and decline in quality of life in patients with motor neuron disease. Cannabinoids have been approved for symptomatic treatment of spasticity in multiple sclerosis. We investigated whether cannabinoids might also reduce spasticity in patients with motor neuron disease. METHODS: We did an investigator-initiated, randomised, double-blind, placebo-controlled, phase 2 clinical trial at four tertiary motor neuron disease centres in Italy. Eligible patients were aged 18-80 years; had possible, laboratory-supported probable, probable, or definite amyotrophic lateral sclerosis as defined by revised El Escorial criteria, or primary lateral sclerosis according to Pringle's criteria; had spasticity symptoms due to motor neuron disease for at least 3 months; had spasticity scores of 1 or greater in at least two muscle groups on the Modified Ashworth Scale; and were taking an antispasticity regimen that was maintained at a stable dose for 30 days before enrolment. Participants were assigned (1:1) by an independent statistician via a computer-generated randomisation sequence to a standardised oromucosal spray (nabiximols) containing a defined combination of delta-9-tetrahydrocannabinol and cannabidiol (each 100 μL actuation contained 2·7 mg delta-9-tetrahydrocannabinol and 2·5 mg cannabidiol) or to placebo for 6 weeks. Participants self-titrated during the first 14 treatment days according to a predefined escalation scheme (maximum 12 actuations per 24 h), then maintained that dose for 4 weeks. The primary endpoint was the change in the score on the Modified Ashworth Scale, which was assessed at baseline and after 6 weeks. Safety and tolerability were also monitored. Participants, investigators, site personnel, and the study statistician were masked to treatment allocation. All randomised participants who received at least one dose of study drug were included in the analysis. This trial is registered with ClinicalTrials.gov, number NCT01776970. The trial is closed to new participants with follow-up completed. FINDINGS: Between Jan 19, 2013, and Dec 15, 2014, 60 participants were randomly assigned, and 59 participants were included in the final analysis (29 in the nabiximols group and 30 in the placebo group). Modified Ashworth Scale scores improved by a mean of 0·11 (SD 0·48) in the nabiximols group and deteriorated by a mean of 0·16 (0·47) in the placebo group (adjusted effect estimate -0·32 [95% CI -0·57 to -0·069]; p=0·013). Nabiximols was well tolerated, and no participants withdrew from the double-blind phase of the study. No serious adverse effects occurred. INTERPRETATION: In this proof-of-concept trial, nabiximols had a positive effect on spasticity symptoms in patients with motor neuron disease and had an acceptable safety and tolerability profile. These findings should be investigated further in larger clinical trials. FUNDING: Italian Research Foundation for Amyotrophic Lateral Sclerosis.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2018. PMID: 30554828. doi:10.1016/S1474-4422(18)30406-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。